An injectable oncolytic hydrogel platform for in situ dendritic cell vaccination to boost antitumor immunity.

Wang ZL, Qiu SY, Sun YQ, Du XJ, Xu CF, Cao ZY, Lu ZD

Biomaterials science27 May 2025Cited by 7 (Europe PMC)

PMID40243662DOI10.1039/d5bm00284bPepBankPUB-40243662

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

01AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In the breast tumor study, LC-Gel containing LTX‑315 and CCL21 triggered immunogenic tumor cell death.
In plain wordsIn animals, the LTX‑315 and CCL21 gel triggered tumor cell death that stimulates immunity.
Peptide
LTX-315
Outcome
IncreaseImmunogenic tumor cell death
Study
n: not reported in source
Orthotopic breast tumors
Outcome group
Immune response · Cancer
Source sentences
Summary
Our findings show that LC-Gel facilitates the intratumoral release of LTX-315, triggering the immunogenic cell death (ICD) of tumor cells and exposing tumor antigens.
1 context sentence(design, population, supporting numbers)
Summary · context
To overcome these limitations, we developed an injectable thermosensitive hydrogel (LC-Gel) that incorporates the oncolytic peptide LTX-315 and the chemokine CCL21 to generate in situ DC vaccines aimed at enhancing anti-tumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4024366201
02AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In the breast tumor study, LC-Gel containing LTX‑315 and CCL21 exposed tumor antigens.
In plain wordsIn animals, the LTX‑315 and CCL21 gel exposed tumor antigens.
Peptide
LTX-315
Outcome
IncreaseTumor antigen exposure
Study
n: not reported in source
Orthotopic breast tumors
Outcome group
Immune response · Cancer
Source sentences
Summary
Our findings show that LC-Gel facilitates the intratumoral release of LTX-315, triggering the immunogenic cell death (ICD) of tumor cells and exposing tumor antigens.
1 context sentence(design, population, supporting numbers)
Summary · context
To overcome these limitations, we developed an injectable thermosensitive hydrogel (LC-Gel) that incorporates the oncolytic peptide LTX-315 and the chemokine CCL21 to generate in situ DC vaccines aimed at enhancing anti-tumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4024366202
03AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In the breast tumor study, sustained CCL21 release from LC-Gel containing LTX‑315 recruited dendritic cells to capture antigens.
In plain wordsIn animals, the LTX‑315 and CCL21 gel recruited immune cells to capture tumor antigens.
Peptide
LTX-315
Outcome
IncreaseDendritic cell recruitment
Study
n: not reported in source
Orthotopic breast tumors
Outcome group
Immune response · Cancer
Source sentences
Summary
Simultaneously, the sustained release of CCL21 from LC-Gel efficiently recruits DCs to capture these antigens, leading to robust T cell activation.
1 context sentence(design, population, supporting numbers)
Summary · context
To overcome these limitations, we developed an injectable thermosensitive hydrogel (LC-Gel) that incorporates the oncolytic peptide LTX-315 and the chemokine CCL21 to generate in situ DC vaccines aimed at enhancing anti-tumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4024366203
04AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In the breast tumor study, LC-Gel containing LTX‑315 and CCL21 led to robust T-cell activation.
In plain wordsIn animals, the LTX‑315 and CCL21 gel activated T cells.
Peptide
LTX-315
Outcome
IncreaseT-cell activation
Study
n: not reported in source
Orthotopic breast tumors
Outcome group
Immune response · Cancer
Source sentences
Summary
Simultaneously, the sustained release of CCL21 from LC-Gel efficiently recruits DCs to capture these antigens, leading to robust T cell activation.
1 context sentence(design, population, supporting numbers)
Summary · context
To overcome these limitations, we developed an injectable thermosensitive hydrogel (LC-Gel) that incorporates the oncolytic peptide LTX-315 and the chemokine CCL21 to generate in situ DC vaccines aimed at enhancing anti-tumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4024366204
05AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In orthotopic breast tumors, LC-Gel containing LTX‑315 and CCL21 enhanced antitumor T-cell immunity.
In plain wordsIn animals, the LTX‑315 and CCL21 gel enhanced T-cell immunity against breast tumors.
Peptide
LTX-315
Outcome
IncreaseAntitumor T-cell immunity
Study
n: not reported in source
Orthotopic breast tumors
Outcome group
Immune response · Cancer
Source sentences
Summary
Consequently, intratumoral injection of LC-Gel generates a potent in situ DC vaccine, enhancing anti-tumor T cell immunity and inhibiting the growth of orthotopic breast tumors.
1 context sentence(design, population, supporting numbers)
Summary · context
To overcome these limitations, we developed an injectable thermosensitive hydrogel (LC-Gel) that incorporates the oncolytic peptide LTX-315 and the chemokine CCL21 to generate in situ DC vaccines aimed at enhancing anti-tumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4024366205
06AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome
In orthotopic breast tumors, LC-Gel containing LTX‑315 and CCL21 inhibited tumor growth.
In plain wordsIn animals, the LTX‑315 and CCL21 gel inhibited breast tumor growth.
Peptide
LTX-315
Outcome
DecreaseBreast tumor growth
Study
n: not reported in source
Orthotopic breast tumors
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Consequently, intratumoral injection of LC-Gel generates a potent in situ DC vaccine, enhancing anti-tumor T cell immunity and inhibiting the growth of orthotopic breast tumors.
1 context sentence(design, population, supporting numbers)
Summary · context
To overcome these limitations, we developed an injectable thermosensitive hydrogel (LC-Gel) that incorporates the oncolytic peptide LTX-315 and the chemokine CCL21 to generate in situ DC vaccines aimed at enhancing anti-tumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4024366206
07AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In the breast tumor study, LC-Gel containing LTX‑315 and CCL21 triggered long-term immune memory for a distant antitumor effect.
In plain wordsIn animals, the LTX‑315 and CCL21 gel triggered long-term immune memory for effects on distant tumors.
Peptide
LTX-315
Outcome
IncreaseLong-term immune memory and distant antitumor effect
Study
n: not reported in source
Orthotopic breast tumors
Outcome group
Immune response · Cancer
Source sentences
Summary
Moreover, LC-Gel is shown to trigger long-term immune memory for eliciting a distant anti-tumor effect.
1 context sentence(design, population, supporting numbers)
Summary · context
To overcome these limitations, we developed an injectable thermosensitive hydrogel (LC-Gel) that incorporates the oncolytic peptide LTX-315 and the chemokine CCL21 to generate in situ DC vaccines aimed at enhancing anti-tumor immunity.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4024366207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.